Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
The FDA Center for Biologics Evaluation and Research (CBER) opened applications in September 2026 for the Expedited IND Pilot program, part of Operation TrialBlazer — the HHS-wide roadmap announced June 22, 2026 coordinating FDA, NIH, ARPA-H, and the HHS Office of Inspector General to keep early clinical research based in the United States. The pilot pairs qualifying sponsors with vetted Qualified Research Institutions to accelerate first-in-human clinical trial initiation for high-priority biologics: cell and gene therapies, therapeutic vaccines, peptide-based biologics, blood-derived products, and other CBER-scope programs. The comment period for the Request for Information runs through 11:59 p.m. ET on September 22, 2026. FDA plans to select up to 10 investigational programs by end of year. The pilot represents the largest FDA process modernization directly targeting biologics IND timing since the 21st Century Cures Act, and matters for the peptide-industry pipeline because peptide-conjugate cancer vaccines, therapeutic peptide vaccines targeting infectious disease, and peptide-antimicrobial biologics all sit within the CBER regulatory scope and would benefit from the accelerated review timeline.
As of Sunday September 6, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now lasted 44 days since the meeting ended on July 24, and compounding pharmacies continue to operate in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation. Formal FDA rulemaking to translate the July PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of just over six weeks is within the normal window but longer than industry advocates had modeled.
AstraZeneca (NASDAQ: AZN) announced Friday September 4, 2026 that the FDA granted accelerated approval to Etcamah (camizestrant, an oral selective estrogen receptor degrader) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone-receptor-positive HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy. FDA also approved the Guardant360 CDx blood-based next-generation sequencing assay as a companion diagnostic to identify ESR1-mutant patients. Approval was based on the Phase 3 SERENA-6 trial that documented a 56% reduction in disease progression or death versus continued standard-of-care aromatase inhibitor plus CDK4/6 inhibitor treatment in the ESR1-mutated subgroup. SERENA-6 was presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine. Etcamah becomes the first oral SERD approved for the switch-at-emergence-of-ESR1 setting, replacing the fulvestrant intramuscular injection historically used post-progression. AstraZeneca is positioning Etcamah alongside Trodelvy plus Datroway as anchors of the expanded breast-cancer franchise.
As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.
Ionis Pharmaceuticals (NASDAQ: IONS) announced Thursday September 3, 2026 FDA approval of Zanvastro (zilganersen, an intrathecally-administered antisense oligonucleotide designed to reduce glial fibrillary acidic protein / GFAP production) for the treatment of Alexander disease in pediatric and adult patients. The approval is the first-ever disease-modifying therapy for Alexander disease, an ultra-rare autosomal dominant neurodegenerative disorder caused by GFAP gene mutations that presents in infancy through adulthood with progressive motor and cognitive decline. Approval landed 19 days ahead of the September 22, 2026 PDUFA target action date. In the registrational trial, walking speed stayed stable in Zanvastro-treated patients while control patients saw a 33% decline. FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV) alongside the approval; PRVs have historically sold for $150-350 million on secondary markets. Zanvastro follows Ionis's Wainua (eplontersen) commercial franchise for hereditary transthyretin amyloid polyneuropathy and lands after the August 28 CARDIO-TTRansform ATTR-CM Phase 3 primary endpoint miss for the same molecule.
Hengrui Pharma (SHA: 600276, HKEX: 1276) disclosed Wednesday September 2, 2026 that China's National Medical Products Administration (NMPA) accepted the marketing authorization application for HRS-7535 (an oral once-daily small-molecule GLP-1 receptor agonist) for long-term weight management in adults with obesity or overweight, plus a separate marketing authorization application for HRS-7535 in type 2 diabetes based on the Phase 3 OUTSTAND-1 and OUTSTAND-2 trials. The Chinese Phase 3 obesity trial delivered mean weight loss of up to 10.9% at Week 44 (11.1% at Week 50 with continued treatment) versus 2.5% for placebo in the 180 mg group. If approved, HRS-7535 would become the first oral small-molecule GLP-1 receptor agonist marketed in China. HRS-7535 is licensed to Kailera Therapeutics (NASDAQ: KLRA) for global rights outside Greater China; the U.S. Phase 3 program is planned to initiate imminently. HRS-7535 would compete with Novo Nordisk's Wegovy pill (oral semaglutide) and Eli Lilly's Foundayo (orforglipron) in oral obesity therapeutics.
Chiesi Group announced Thursday September 3, 2026 that the European Medicines Agency validated regulatory submissions for the Single Inhaler Triple Therapy (Trimbow, beclomethasone dipropionate / formoterol fumarate / glycopyrronium bromide) and the ICS/LABA combination (Fostair, beclomethasone dipropionate / formoterol fumarate) reformulated with HFA-152a — a next-generation non-PFAS propellant with low global warming potential. The reformulated pressurized metered-dose inhalers are designed to reduce the carbon footprint of the products by up to 90% versus the current HFA-134a formulations. In July 2026, the UK Medicines and Healthcare products Regulatory Agency approved Chiesi's beclomethasone pMDI with HFA-152a as the first UK approval of the next-generation propellant. The Chiesi Carbon Minimal Inhaler program is the pharmaceutical industry's leading environmental sustainability initiative and provides a template for GSK, AstraZeneca, and Teva reformulation of Ellipta/Advair/Symbicort/ProAir portfolios that account for approximately 3% of the UK NHS carbon footprint.
The U.S. Food and Drug Administration confirmed via press announcement Friday September 4, 2026 that it will convene a joint workshop with the European Medicines Agency (EMA) on Friday September 25, 2026 to discuss regulatory considerations for herbal medicinal and botanical drug products intended for medicinal use. The workshop follows the FDA's ongoing public-input process on botanical drug development that generated substantial biotech and pharmaceutical industry commentary earlier in 2026. Botanical drugs occupy an underdeveloped regulatory category in the U.S. — FDA has approved only two botanical drugs to date (Veregen sinecatechins from green tea for genital warts, approved 2006; Fulyzaq crofelemer from Croton lechleri sap for HIV-related diarrhea, approved 2012). Proposed legislation in the U.S. would extend 12-year market exclusivity to FDA-approved botanical drugs, matching the biologics exclusivity framework. The Sept 25 workshop matters for the peptide-industry pipeline because plant-derived and marine-organism-derived peptide products (defensins, ranatuerin analogs, plant-defensin-based antimicrobials) occupy a similar regulatory gray zone between conventional pharmaceuticals and dietary supplements.
uniQure N.V. (NASDAQ: QURE) announced Wednesday September 2, 2026 the submission of a Biologics License Application (BLA) to the U.S. FDA for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational AAV-delivered gene therapy for the treatment of Huntington's disease. The BLA is the first ever submitted for a Huntington's disease therapy of any kind. AMT-130 is delivered by stereotactic intraparenchymal injection into the striatum and expresses a microRNA designed to silence the mutant huntingtin (mHTT) gene. The submission is supported by three-year data from the Phase 1/2 program compared to a propensity score-matched external control from the Enroll-HD natural history database. uniQure also submitted a Marketing Authorisation Application (MAA) to the UK MHRA on the same day. A four-year data readout from the ongoing Phase 1/2 study is expected before end of Q3 2026. AMT-130 previously received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Approval would establish the first disease-modifying therapy for Huntington's, where standard-of-care remains symptom management with tetrabenazine and deutetrabenazine plus antipsychotics.
As of Thursday September 3, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence extends the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2 and continues to leave compounding pharmacies operating under enforcement risk. CDER warning-letter activity to compounding pharmacies remained elevated through Q3 2026 versus prior years. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled; formal FDA rulemaking to translate PCAC recommendations into a proposed rule typically runs 6 to 18 months. The FDA Commissioner nomination of Dr. Heidi Overton continues to await Senate confirmation, with acting Commissioner Kyle Diamantas leading the agency through the interim.
The FDA Center for Biologics Evaluation and Research (CBER) confirmed Wednesday September 2, 2026 that the previously-announced Phase 1 fast-track IND pilot program is opening applications during September 2026, with up to 10 investigational programs selected by year end. The pilot follows the Center for Drug Evaluation and Research (CDER) parallel pilot announced earlier in 2026 and is designed to accelerate first-in-human clinical trial initiation for high-priority biologics (including cell and gene therapies, therapeutic vaccines, peptide-based biologics, and blood-derived products). The pilot matters for the peptide-industry pipeline because peptide-conjugate cancer vaccines, therapeutic peptide vaccines targeting infectious disease, and peptide-antimicrobial biologics all sit within the CBER regulatory scope and would benefit from the accelerated review timeline. Selection criteria emphasize unmet medical need, novel mechanism, and preclinical data quality; individual selection results will not be public.
Ultragenyx Pharmaceutical (NASDAQ: RARE) awaits its September 19, 2026 PDUFA target action date for UX111 (rebisufligene etisparvovec, an AAV9 gene therapy delivering the SGSH gene) for the treatment of Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA, MPS IIIA, a rare autosomal recessive lysosomal storage disorder caused by SGSH gene mutations that results in progressive cognitive decline in early childhood and death typically by the second decade). If approved, UX111 would become the first FDA-approved therapy for MPS IIIA, where the current standard of care remains supportive symptom management. The AAV9-based intravenous delivery approach mirrors the Novartis Zolgensma (onasemnogene abeparvovec) commercial template for spinal muscular atrophy and continues the neurometabolic gene therapy pipeline. Not a peptide, but the approval would extend the AAV gene therapy commercial category that has continued to reshape the rare-disease landscape alongside enzyme replacement therapies and the emerging small-molecule chaperone class.
Merck (NYSE: MRK) awaits its September 21, 2026 PDUFA target action date for a further label expansion of Winrevair (sotatercept-csrk, an activin signaling inhibitor administered as subcutaneous injection every three weeks) in pulmonary arterial hypertension (PAH). Winrevair was originally FDA-approved March 26, 2024 for adults with PAH (WHO Group 1) to increase exercise capacity, improve WHO functional class, and reduce risk of clinical worsening events, based on the Phase 3 STELLAR trial. The pending label expansion is expected to cover an earlier line of therapy and/or a broader patient population based on the ZENITH and HYPERION Phase 3 trials that reported earlier in 2026 (ZENITH: PAH high-risk patients on maximal background therapy; HYPERION: newly diagnosed PAH). The Winrevair franchise reached $260 million in Q2 2026 revenue and is on track to reach $1 billion annual run rate before end of 2026. Sotatercept-csrk is a fusion protein of activin receptor type IIA and the Fc portion of human immunoglobulin.
Ionis Pharmaceuticals (NASDAQ: IONS) awaits its September 22, 2026 PDUFA target action date for zilganersen (an intrathecally-administered antisense oligonucleotide designed to reduce production of glial fibrillary acidic protein / GFAP) for the treatment of Alexander disease, a rare autosomal dominant neurodegenerative disease caused by GFAP gene mutations. If approved, zilganersen would become the first FDA-approved therapy for Alexander disease and Ionis's next commercial launch following Wainua (eplontersen) for hereditary transthyretin amyloid polyneuropathy (with the CARDIO-TTransform ATTR-CM primary endpoint miss now behind the company). Zilganersen was granted FDA Fast Track designation and Orphan Drug designation. Alexander disease presents in infancy through adulthood with progressive motor and cognitive decline; no disease-modifying therapies are currently approved. Not a peptide, but the antisense oligonucleotide class continues to complement peptide-based rare-disease therapies (Rein Therapeutics LTI-03 Caveolin-1 peptide for IPF among others) as the RNA modality expands into ultra-orphan indications.
The Trump administration's landmark November 6, 2025 GLP-1 drug pricing agreement with Eli Lilly and Novo Nordisk continues implementation through September 2026 with the TrumpRx.gov direct-to-consumer platform on schedule for January 2026 launch. Terms confirmed as of September 1, 2026: starting doses of Wegovy and Zepbound available at $350/month on TrumpRx (trending down to $245/month over a two-year period); Medicare prices set at $245/month for Ozempic, Wegovy, Mounjaro, and Zepbound, with Medicare beneficiaries paying $50/month copays; upcoming oral obesity pills (Lilly Foundayo, Novo Wegovy pill) priced at $149/month for Medicare, Medicaid, and TrumpRx patients. The Most-Favored-Nation pricing framework requires both companies to guarantee MFN prices on all new medications and repatriate increased foreign revenue on existing products. The agreement extends Medicare coverage to Wegovy and Zepbound for obesity plus related comorbidities for the first time, ending the Medicare Part D exclusion that has constrained the class since launch.
Rein Therapeutics (NASDAQ: RNTX) received UK Medicines and Healthcare products Regulatory Agency (MHRA) clearance in August 2026 to initiate the Phase 2 RENEW study of LTI-03 (a Caveolin-1 scaffolding domain peptide mimetic developed for the treatment of idiopathic pulmonary fibrosis, or IPF). The RENEW study is planned to enroll 120 patients with IPF and evaluate LTI-03 as an add-on to standard-of-care antifibrotic therapy (pirfenidone or nintedanib). The Caveolin-1 mimetic peptide mechanism engages the fibrotic signaling that emerges downstream of alveolar epithelial cell injury and has been characterized in preclinical fibrosis models. Rein Therapeutics is the successor entity to the 2024 reverse merger between Aileron Therapeutics and Lung Therapeutics, and LTI-03 is the lead clinical asset. The Phase 2 initiation extends the small-but-substantive peptide-therapeutic pipeline in fibrotic disease (Sitryx SIT-402, MediciNova ibudilast) beyond the incretin obesity focus that dominates recent peptide-industry headlines.
PharmaEssentia announced Sunday August 30, 2026 FDA approval of BESREMi (ropeginterferon alfa-2b-njft, a monopegylated proline-modified recombinant interferon alfa-2b protein administered as biweekly subcutaneous injection) for adults with essential thrombocythemia (ET), a chronic BCR-ABL-negative myeloproliferative neoplasm characterized by excessive platelet production and increased thrombotic and hemorrhagic risk. Approval was received at the August 30 PDUFA target action date under the supplemental BLA that the FDA accepted January 2026. The approval covers adults with ET regardless of genotype or disease status (including newly-diagnosed patients naive to cytoreductive therapy) and expands the existing BESREMi commercial label (approved for polycythemia vera in November 2021). BESREMi is the first FDA-approved therapy for ET in nearly three decades — the standard-of-care landscape has been dominated by cytoreductive hydroxyurea, anagrelide, and off-label pegylated interferons plus low-dose aspirin. The ET approval follows the June 2026 Taiwan approval that marked BESREMi's first global regulatory clearance in ET.
Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.